Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2011 / Article

Original Article | Open Access

Volume 2011 |Article ID 167684 | https://doi.org/10.1093/ecam/neq004

Chutwadee Krisanapun, Seong-Ho Lee, Penchom Peungvicha, Rungravi Temsiririrkkul, Seung Joon Baek, "Antidiabetic Activities of Abutilon indicum (L.) Sweet Are Mediated by Enhancement of Adipocyte Differentiation and Activation of the GLUT1 Promoter", Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 167684, 9 pages, 2011. https://doi.org/10.1093/ecam/neq004

Antidiabetic Activities of Abutilon indicum (L.) Sweet Are Mediated by Enhancement of Adipocyte Differentiation and Activation of the GLUT1 Promoter

Received20 Aug 2009
Accepted01 Jan 2010
Published17 Feb 2011


Abutilon indicum (L.) Sweet is an Asian phytomedicine traditionally used to treat several disorders, including diabetes mellitus. However, molecular mechanisms supporting the antidiabetic effect of A. indicum L. remain unknown. The aim of this study was to evaluate whether extract of A. indicum L. improves insulin sensitivity. First, we observed the antidiabetic activity of aqueous extract of the entire plant (leaves, twigs and roots) of A. indicum L. on postprandial plasma glucose in diabetic rats. The subsequent experiments revealed that butanol fractions of the extract bind to PPARγ and activate 3T3-L1 differentiation. To measure glucose uptake enhanced by insulin-like activity, we used rat diaphragm incubated with various concentrations of the crude extract and found that the extract enhances glucose consumption in the incubated solution. Our data also indicate that the crude extract and the fractions (water and butanol) did not affect the activity of kinases involved in Akt and GSK-3β pathways; however, the reporter assay showed that the crude extract could activate glucose transporter 1 (GLUT1) promoter activity. These results suggest that the extract from A. indicum L. may be beneficial for reducing insulin resistance through its potency in regulating adipocyte differentiation through PPARγ agonist activity, and increasing glucose utilization via GLUT1.

1. Introduction

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both; the incidence of diabetes is increasing worldwide. Diabetes or obesity causes substantial morbidity, mortality and long-term complications, and remains an important risk factor for cardiovascular disease [1]. There exists a genetic predisposition to diabetes; however, environmental factors such as a sedentary lifestyle and obesity are the most prominent risk factors [2]. Insulin resistance is a key feature in type 2 DM as well as in obesity and plays an important pathophysiological role [3]. Insulin resistance is characterized by a diminished reaction of insulin-sensitive tissues and a marked decrease in glucose metabolism in response to insulin. In fact, impairment of insulin action has also been observed in syndromes including inflammatory and chronic infectious diseases in addition to type 2 DM [4]. Recent data suggest that activation of PPARγ by using plant extracts improves lipid metabolism and mitigates insulin resistance [5]. Throughout the world, many traditional plant treatments for diabetes are employed that are frequently considered to be less toxic and have fewer side effects than synthetic drug treatments [1, 6]. According to a medicinal survey report in Thailand, traditional medicines or herbs are used 31% of the time in the treatment of diabetic patients [7]. However, traditional antidiabetic plants possess less adequate scientific or medicinal data support in spite of the fact that the World Health Organization still recommends further evaluation of their accepted use [8, 9].

The native Southeast Asian plant A. indicum (L.) Sweet is an erect, branched shrub of 0.5–1 m height, having the Thai name Krob-Fun-Si, Fun-Si or Ma-Kong-Khaao. A. indicum L. is in the family Malvaceae, is easily identified by its cog-like fruits, and is found abundantly in wastelands. This plant has a long history of being used medicinally as an antidiabetic remedy, and phytochemical screening of the plant revealed that it contained alkaloids, flavonoids, tannins, saponins and glycosides [10, 11]. This medicinal plant plays an important role in folk medicine; in Thailand, it has been used as a blood tonic, carminative, antipyretic, anti-cough, diuretic, anti-inflammatory, laxative and antidiabetic [12], whereas in India and China, it has been used for urinary disease, gonorrhea, jaundice, rheumatism, high fever, mumps, pulmonary tuberculosis, bronchitis, lack of urination and some nervous and ear problems [13, 14]. According to many scientific reports, the leaf extracts possess hypoglycemic, hepatoprotective, antibacterial and larvicidal properties [10, 13, 15, 16]. Analgesic principles from this plant were also isolated [17], and its polyherbal formulations have been reported as being effective in treating diabetes and hyperlipidemia, and effective as free radical scavengers [1820].

With respect to its traditional use, A. indicum L. has been known to contain an active ingredient against diabetes and is believed to reduce some symptoms of diabetic complications. In this study, we investigated whether the extracts of A. indicum L. could reduce postprandial plasma glucose levels in an animal model of diabetes, since postprandial hyperglycemia is one of the common complications seen in diabetic patients [21]. We found that A. indicum L. ameliorates insulin resistance via PPARγ activation and enhances glucose uptake.

2. Methods

2.1. Plant Material

The leaves, twigs and roots of A. indicum (L.) Sweet were collected from Mahidol University, Salaya Campus, Nakorn Pathom Province, Thailand, during May 2004, and were authenticated by Rungravi Temsiririrkkul, Department of Pharmaceutical Botany, Faculty of Pharmacy, Mahidol University. A voucher specimen (PBM 04765) was deposited at the Pharmaceutical Botany Mahidol University herbarium. All fresh parts were dried at 50°C in a hot air oven and then pulverized by an electric blender. Crude extract was obtained by boiling 1 kg of plant powder (leaves 261.2 g, twigs 559.7 g and root 179.1 g) in 10 l of distilled water for 10 min. The boiling process was repeated twice, and the combined extract was filtered across cotton wool and gauze. The filtrate was lyophilized in a freeze dry system resulting in a dark brown powder of 11.44% w/w. Lyophilized extract was preserved in an airtight bottle at room temperature and protected from light until use. The crude extract (10 g) was subsequently partitioned between butan-1-ol (3 × 0.2 l) and distilled water (0.2 l). The butanol fraction was concentrated under reduced pressure in a rotary evaporator and lyophilized to give a total semi-solid residue (19% of dried crude extract). The resulting water fraction was freeze-dried, followed by generating brown powder (65.4% of dried crude extract).

2.2. Animals

Male Wistar rats, weighing 140–180 g, were purchased from the National Laboratory Animal Center, Mahidol University, Salaya, Nakorn Pathom Province, Thailand. They were housed in a temperature-controlled room (22–25°C) with a 12 h light-dark cycle for at least 1 week to acclimatization. The animals were fed with free access to a commercial pellet diet (C.P. Thailand) and water ad libitum. The animal protocol was approved by the Animal Ethics Committee, Faculty of Pharmacy, Mahidol University (No. 5/2548).

2.3. Preparation of Diabetic Rats

Diabetes was induced in the 16 h-fasted male Wistar rats with a single intraperitoneal injection of 75 mg kg−1 streptozotocin (STZ), freshly dissolved in isotonic saline. Five days after injection, diabetic rats were identified by measuring fasting plasma glucose (FPG) levels using PGO enzyme (Sigma). Rats with FPG levels over 200 mg dl−1 were used in the experiment [22, 23].

2.4. Antidiabetic Activity of A. indicum Extract on Postprandial Plasma Glucose

The STZ-induced diabetic rats were randomly allocated into four groups (6–9 rats per group) A. indicum crude extract and glibenclamide were dissolved in distilled water and administered orally once a day for 2 weeks as follows: Group 1: diabetic rats treated orally with distilled water (control), Group 2: diabetic rats treated orally with glibenclamide 5 mg kg−1 body weight (positive control), Groups 3 and 4: diabetic rats treated orally with crude extract 0.25 or 0.5 g kg−1 body weight. Blood samples (60 μl of each) were collected from the tail vein using Hematocrit-capillary tube, after 2 h fasting on day 0 (1 day before oral administration), day 7 and day 14 for plasma glucose determination. The animals were weighed on day 0, 4, 7, 11 and 14 for corrected doses of medication.

2.5. Cell Cultures

HCT-116, HepG2, C2C12, 3T3-L1 and L6 cells were purchased from American Type Culture Collection (Manassas, VA, USA). HCT-116 cells were maintained in McCoy’s 5A medium supplemented with 10% FBS; all others were maintained in DMEM supplemented with 10% FBS. Cells were grown at 37°C in a humidified, 5% CO2 environment. For adipocyte differentiation, differentiation medium containing 0.5 mM isobutyl methylxanthine, 1 μM dexamethasone and 1 μg ml−1 insulin was added to the culture. The differentiation media was changed every 2 days until day 4. Thereafter, DMEM containing 10% FBS and insulin was subsequently replaced every 2 days until day 8. C2C12 and L6 myoblasts were differentiated with DMEM containing 2% horse serum for 6 and 2 days, respectively.

2.6. Binding Activity of A. indicum Extract to PPARα and PPARγ

HCT-116 cells were plated in 12-well plates at a concentration of 2 × 105 cells/well. After growth for 18 h, transient transfections were performed using lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. MH 100×4-TK-LUC plasmid, pCMX-Gal-mPPARα-LBD, and pCMX-Gal-mPPARγ-LBD (0.25 μg each) were co-transfected with pRL-null vector (0.05 μg) into the cells. The transfected cells were cultured in the absence or presence of various concentrations of crude extract, water or butanol fraction for 24 h. Cells were harvested in 1× luciferase lysis buffer, and luciferase activity was normalized to the pRL null luciferase activity using a dual luciferase assay kit (Promega, Madison, WI, USA). Assays were performed in triplicate for each experiment group as previously described [24].

2.7. Analysis of mRNA Expression during Adipocyte Differentiation

Total RNA was extracted from 3T3-L1 cells at day 0 (before differentiation), 2, 4, 6 and 8 after differentiation using the PerfectPure RNA purification kit according to the manufacturer’s instructions (5Prime, Gaithersburg, MD, USA). Reverse transcription (RT) was performed on 1 μg of RNA samples using an iScript cDNA synthesis kit in a final volume of 20 μl, according to the manufacturer’s instructions (Bio Rad, Hercules, CA, USA). Specific oligonucleotide primers were designed using the Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Quantitative changes in mRNA expression were assessed with a semi-quantitative RT-PCR, using specific primers (Table 1). The PCR products were separated electrophoretically in a 2% agarose gel and stained with ethidium bromide.


AdiponectinForward5′-TGC ACA GCT CCG TGT ACT TC-3′





2.8. Glucose Consumption Assay

Adult male Wistar rats weighing 180–200 g were used in this experiment. Animals were fasted for 36 h and sacrificed by inhalation of diethyl ether. The thorax was opened, and the diaphragm was removed. The diaphragm was immediately placed in oxygenated nutrient solution (125 ml of aerated 1.3% NaHCO3 was added to 750 ml of 0.16 M NaCl, 5.4 mM KCl, 2.7 mM CaCl2, 4.2 mM NaHCO3, 1.4 mM MgSO4·7H2O, and 1.5 mM KH2PO4). The diaphragm was cleaned of fat and connective tissue and cut into 6 pieces before being suspended in a nutrient solution organ bath containing 300 mg dl−1 of glucose and bubbled with carbogen at 37°C [25]. Then, the crude extracts or insulin (used as the positive control) was added as follows: Group 1: incubated in only nutrient solution (control group), Group 2: crude extract at a concentration of 0.04 mg dl−1, Group 3: crude extract at a concentration of 0.2 mg dl−1, Group 4: crude extract at a concentration of 1.0 mg dl−1, Group 5: crude extract at a concentration of 5.0 mg dl−1, and Group 6: insulin 1 unit ml−1 (positive control). After 90 min of incubation, the concentration of remaining glucose in the solution was measured, and each piece of diaphragm was dried. The results were expressed as glucose consumption per 10 mg dry diaphragm.

2.9. GLUT1 Luciferase Reporter Assay

L6 myocytes in 48-well plates were co-transfected using FuGENE6 (Roche, Indianapolis, IN, USA) with 0.25 μg GLUT1 promoter (generously provided by Dr Birnbaum at the University of Pennsylvania, Philadelphia, PA, USA) and 0.025 μg of pRL-SV40 plasmid. After 30 h of transfection, cells were exposed to various concentrations of crude extract in HEPES-buffered saline, pH 7.4, containing 2% horse serum with 5 mM glucose for 16 h. The cells were washed twice with PBS and then assayed for luciferase activity as shown above.

2.10. Statistical Analysis

The data were presented as the mean ± standard error of the mean (SEM). Statistical analysis was performed using the Student’s t-test or analysis of variance (ANOVA) followed by the least significant differences (LSD) test. The significance of differences was set at P-value < .05.

3. Results

3.1. Postprandial Plasma Glucose in STZ-Induced Diabetic Rats

As shown in Figure 1, administration of A. indicum crude extract significantly lowered (P < .05) 2 h postprandial plasma glucose concentrations of treated groups in comparison to those of control STZ-diabetic rats at the corresponding time. A similar significant decrease was also observed in rats treated with glibenclamide. However, prior to treatment administration (day 0), basal plasma glucose concentration did not significantly differ between groups.

3.2. Binding Activity to Peroxisome Proliferator-Activated Receptors

To examine whether A. indicum extracts activate peroxisome proliferator-activated receptor (PPAR) responsiveness, HCT-116 cells were transfected with four copies of a Gal4 binding site (MH100x4-TK-LUC) and chimeric receptors (pCMX-Gal-mPPARα-LBD or pCMX-Gal-mPPARγ-LBD). In this system, when a compound binds to the ligand binding domain (LBD) of the PPARα or PPARγ chimeric receptor, the DNA binding domain of the yeast Gal4 binds to the co-transfected Gal4 binding site and initiates transcription of the firefly luciferase (LUC). After cells were treated with crude extract for 24 h, luciferase activities were measured to assess the transactivation for each PPAR receptor. As shown in Figures 2(a) and 3(a), crude extract 100 μg ml−1 showed 1.6- and 1.4-fold increases of transactivation to PPARα and PPARγ, respectively, indicating that crude extract contains compounds that bind to PPARα and PPARγ.

The activation of PPARα and PPARγ using water and butanol fractions was also investigated. The results revealed that the water fraction has a minimal effect on PPARα and PPARγ activation, whereas butanol fractions showed a dose-dependent increase of PPARα and PPARγ activation (Figures 2(b) and 3(b)). The concentration of butanol fraction (100 μg ml−1) showed 5.5- and 3.2-fold increases of transactivation to PPARα and PPARγ, respectively. These results suggest that the butanol fraction, but not the water fraction, contains a substance that activates PPARα and PPARγ.

3.3. mRNA Expression during Preadipocyte Differentiation

Since butanol fraction binds to PPARγ and transactivates PPARγ activity, gene expression profiles were observed to elucidate whether the butanol fraction actually induces adipocyte differentiation through PPARγ activation. Twenty-four hours before and during differentiation, butanol fraction at 100 μg ml−1 was added to the medium for observation of its effects on gene expression during 3T3-L1 adipocyte differentiation. Dimethyl sulfoxide (DMSO) was used as vehicle control. As shown in Figure 4, cells treated with the butanol fraction increased the expression of PPARγ, aP2, and adiponectin at day 8, consistent with the previous data indicating that butanol fraction enhances PPARγ activity (Figure 3(b)). However, there was no change in mRNA level of lipoprotein lipase (LPL) throughout the differentiation.

3.4. Glucose Consumption

Crude extract of A. indicum was tested for insulin-like effect using diaphragm of rat. Pieces of diaphragms were incubated with various concentrations of the crude extract for 1.5 h. As shown in Figure 5, the extract enhanced glucose uptake in a concentration-dependent manner. The extract between concentrations of 1–5 mg ml−1 significantly increased glucose uptake and showed an almost maximal effect on glucose uptake at the concentration of 1 mg ml−1. Insulin was used as a positive control and also showed an ~1.7-fold induction over the untreated group.

3.5. Protein Expression in Insulin Signaling Pathway and GLUT1 Promoter Activation

Since protein kinases B (Akt) and glycogen synthase kinase 3β (GSK3β) are major kinases of the insulin signaling pathway [26, 27], the effects of crude extract and butanol and water fractions on phosphorylation of Akt and GSK3β in C2C12 myotubes and 3T3-L1 adipocytes were examined. However, no changes were detected in Akt phosphorylation or GSK3β phosphorylation, although insulin activated these two biochemical markers (data not shown), suggesting that extracts and fractions do not affect the Akt/GSK3β pathway. To determine the effect of crude extract on the transcriptional activity of Glut1, a pGL3-GLUT1 luciferase construct that contains –2100 bp of the rat Glut1 promoter region was transfected into L6 cells. After transfection, the cells were treated with various concentrations of crude extract for 16 h, and luciferase activity was measured. As shown in Figure 6, the cells treated with the extract increased relative luciferase unit (RLU) in a dose-response manner. A significant fold increase against untreated cells was found in the cells treated with 100 and 500 μg ml−1 of crude extract.

4. Discussion

Much research effort is currently directed toward development of adipogenesis and lipogenesis studies, and a number of antidiabetic compounds have been developed and tested for their effects. For example, thiazolidinediones (TZDs), synthetic PPARγ ligands, are a novel class of antidiabetic drugs for patients with type 2 diabetes, and two of these, rosiglitazone and pioglitazone, are currently available for clinical use [28]. Originally, TZDs were identified based on their antihyperglycemic activity, but they are also able to improve other abnormalities associated with type 2 diabetes, such as hyperlipidemia, atherosclerosis, hypertension, chronic inflammation and fibrinolytic state. It is well established that PPARγ agonists such as TZDs promote the adipogenesis of 3T3-L1 cells, which have been used for the development of antidiabetic compounds [2931]. Since troglitazone (TGZ) was voluntarily withdrawn from the market in March 2000 due to occurrence of severe idiosyncratic liver injury, it is necessary to establish a safer compound that shows antidiabetic activity. Many researchers have focused on the study of dietary phytochemicals found in plants. In this report, we examined whether the extract of A. indicum has antidiabetic activity in STZ-induced diabetic rats. The results demonstrated that administration of A. indicum extract at 0.25 and 0.5 g kg−1 resulted in significant decreases of postprandial plasma glucose, as seen in glibenclamide-treated rats. Although glibenclamide lowers plasma glucose level, mainly by stimulating insulin secretion from pancreatic β-cells [32], destruction of β-cells are observed in STZ-induced diabetes model (type 1 diabetes) [33]. Thus, extrapancreatic action such as stimulating liver and muscle fructose-2,6-bisphosphate formation may be involved in the effect of both glibenclamide and extracts used in this study rather than insulin secretion. In fact, it has been known that the extrapancreatic action of glibenclamide has an important role to inhibit glucose production by liver and improve carbohydrate metabolism in diabetes [34, 35], and increases glucose disposal by stabilizing GLUT1 protein at the plasma membrane of muscle [36]. Subsequently, we found that crude extract of A. indicum acts as a PPARγ ligand. Further, the data indicated that the butanol fraction (non-polar part) may contain a compound that induces PPARγ activity (Figure 3(b)). The present study also demonstrates that the butanol fraction enhances 3T3-L1 adipocyte differentiation by an increase of accumulation of differentiation and fat cell marker genes (Figure 4). The accumulation of these mRNA reflects both the rate of initiation of transcription and the half time of degradation of those transcripts.

At the molecular level, adipogenesis is driven by a complex transcriptional cascade involving the sequential activation of CCAAT/enhancer binding proteins (C/EBPs) and PPARγ [37]. Loss-of-function studies have convincingly shown that PPARγ is necessary as well as sufficient to promote adipogenesis and that C/EBPα is influential by maintaining the expression of PPARγ and promoting full insulin sensitivity [38]. Our data indicate that exposing 3T3-L1 preadipocytes to the butanol fraction during adipogenesis increases PPARγ mRNA, as well as the adipocyte-specific fatty acid binding protein (aP2) mRNA level; aP2 is one of the genes that characterizes the adipocyte phenotype [37, 39]. Interestingly, the mRNA level of adiponectin in the butanol fraction-treated group was higher than the control throughout the differentiation. Adiponectin is exclusively expressed by mature adipocytes and is the most abundant circulating adipokine. Thus, these data imply that the butanol fraction of A. indicum extract enhances adipogenesis through PPARγ activation. Hypoadiponectinemia appears to play an important causal role in insulin resistance, type 2 DM and metabolic syndrome [40, 41]. We could not exclude the possibility that butanol fraction affects mRNA stability of those genes, and further studies may require elucidating the molecular mechanism by which butanol fraction affects gene induction during adipogenesis. Since LPL (a PPARγ target gene) did not increase in the presence of butanol fraction, it is possible that butanol fraction may affect gene induction in a PPARγ-independent manner. The data also showed that butanol fraction increased the activity of PPARα; however, further work to investigate expression of the PPARα target gene is required to claim that the extract of A. indicum acts as a PPARα/γ dual agonist. Indeed, PPARα agonists, such as fibrates, have been used to treat hypertriglyceridemia and reduce cardiovascular risk [42]. Dual PPARα/γ agonists hold promise to be able to combine the properties of TZDs and fibrates, as well as improve the management of type 2 diabetes and provide an effective therapeutic option for treating the multifactorial components of cardiovascular disease, metabolic syndrome [43], and even cancer.

Another important finding of this work is that the extract of A. indicum possessed considerable insulin-like properties, as evidenced by enhancement of glucose uptake in the diaphragm, which represents muscle cells that are the major site of insulin-stimulated glucose disposal [44]. In the follow-up studies, we examined potential mechanisms underlying the improvement in glucose utilization by the extract. The defective glucose transport system may play an important role in the pathogenesis of peripheral insulin resistance, and glucose uptake in target tissues is a critical step in maintaining glucose homeostasis and in clearing the postprandial glucose load [45]. Thus, we examined the possibility that the extract may stimulate glucose transport through a mechanism similar to insulin signaling in C2C12 myotubes and 3T3-L1 adipocytes. Previous literature has documented that the phosphatidylinositol-3-kinase (PI3K) pathway plays an important role in the insulin signaling cascade leading to glucose transport translocation [44]. However, the results showed that under basal or insulin-stimulated conditions, all of the extract treatments (crude extract, water and butanol fraction) had no effect on Akt serine phosphorylation in either cell type (data not shown). Another pathway that has been implicated in glucose transport, not by translocation of GLUT, but by activation of GLUT, is the p38 pathway [46], which is also interesting for further study. This pathway has been reported to be involved in the regulation of GLUT 1 expression [47]. Subsequently, we examined the effect of the extract on transcription activation of GLUT1. As demonstrated in this study, extract of A. indicum activated transcription of GLUT1 in a dose-response manner, suggesting involvement of GLUT1 in increasing glucose uptake by the extract. This result will require confirmation such as measuring extracellular signal regulated kinases (ERKs), which have been known to be responsible for the expression of GLUT1 [48].

We have reported that the phytochemical analysis of the whole plant extract revealed the presence of alkaloids, flavonoids, and tannins [11]. Results from other researchers have shown that this plant also contains saponins and glycosides [10]. Most plants with antidiabetic properties have been found to contain metabolites such as glycosides, alkaloids and flavonoids [9]. Indeed, seven compounds were isolated from A. indicum extract and six of them identified as β-sitosterol, oleanolic acid, (24R)-α-stigmastane-3,6-dione, daucosterol, 2,6-dimethoxy-1,4-benzoquinone, and vanillic acid [49]. Oleanolic acid has been reported to have hypoglycemic activity by acting as an inhibitor of glycogen phosphorylase, leading to the inhibition of hepatic glycogenolysis [50]. The alkaloid berberine has also been reported to activate GLUT1-mediated glucose uptake [48]. Thus, these results provide evidence that these compounds may lead to affect the antidiabetic activity of A. indicum. The findings of antidiabetic properties in this study are summarized in Figure 7, and support the ethnobotanical use of A. indicum in the context of human type 2 DM; however, the molecules of action responsible for A. indicum’s effect remain to be identified.


The Center of Excellence in Livestock Diseases and Human Health at the University of Tennessee and a National Institutes of Health grant (R21CA109423). Financial support was provided by the Royal Golden Jubilee PhD Program (PHD/0245/2545) and the Office of the Higher Education Commission, Thailand (to C.K.).


The authors thank Misty Bailey for her critical reading of manuscript.


  1. G. Y. Yeh, D. M. Eisenberg, T. J. Kaptchuk, and R. S. Phillips, “Systematic review of herbs and dietary supplements for glycemic control in diabetes,” Diabetes Care, vol. 26, no. 4, pp. 1277–1294, 2003. View at: Publisher Site | Google Scholar
  2. S. Samane, J. Noël, Z. Charrouf, H. Amarouch, and P. S. Haddad, “Insulin-sensitizing and anti-proliferative effects of Argania spinosa seed extracts,” Evidence-Based Complementary and Alternative Medicine, vol. 3, no. 3, pp. 317–327, 2006. View at: Publisher Site | Google Scholar
  3. P. Vollenweider, “Insulin resistant states and insulin signaling,” Clinical Chemistry and Laboratory Medicine, vol. 41, no. 9, pp. 1107–1119, 2003. View at: Publisher Site | Google Scholar
  4. T.-P. Liu, C.-S. Lee, S.-S. Liou, I.-M. Liu, and J.-T. Cheng, “Improvement of insulin resistance by Acanthopanax senticosus root in fructose-rich chow-fed rats,” Clinical and Experimental Pharmacology and Physiology, vol. 32, no. 8, pp. 649–654, 2005. View at: Publisher Site | Google Scholar
  5. C.-C. Shih, C.-H. Lin, W.-L. Lin, and J.-B. Wu, “Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats,” Journal of Ethnopharmacology, vol. 123, no. 1, pp. 82–90, 2009. View at: Publisher Site | Google Scholar
  6. P. S. Haddad, G. A. Azar, S. Groom, and M. Boivin, “Natural health products, modulation of immune function and prevention of chronic diseases,” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 4, pp. 513–520, 2005. View at: Publisher Site | Google Scholar
  7. W. Aekplakorn, R. P. Stolk, B. Neal et al., “The prevalence and management of diabetes in Thai adults: the International Collaborative Study of Cardiovascular Disease in Asia,” Diabetes Care, vol. 26, no. 10, pp. 2758–2763, 2003. View at: Publisher Site | Google Scholar
  8. A. M. Gray, Y. H. A. Abdel-Wahab, and P. R. Flatt, “The traditional plant treatment, Sambucus nigra (elder), exhibits insulin-like and insulin-releasing actions in vitro,” Journal of Nutrition, vol. 130, no. 1, pp. 15–20, 2000. View at: Google Scholar
  9. A. A. Odetola, O. Akinloye, C. Egunjobi, W. A. Adekunle, and A. O. Ayoola, “Possible antidiabetic and antihyperlipidaemic effect of fermented Parkia biglobosa (JACQ) extract in alloxan-induced diabetic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 9, pp. 808–812, 2006. View at: Publisher Site | Google Scholar
  10. Y. N. Seetharam, G. Chalageri, S. R. Setty, and Bheemachar, “Hypoglycemic activity of Abutilon indicum leaf extracts in rats,” Fitoterapia, vol. 73, no. 2, pp. 156–159, 2002. View at: Publisher Site | Google Scholar
  11. C. Krisanapun, P. Peungvicha, R. Temsiririrkkul, and Y. Wongkrajang, “Aqueous extract of Abutilon indicum Sweet inhibits glucose absorption and stimulates insulin secretion in rodents,” Nutrition Research, vol. 29, no. 8, pp. 579–587, 2009. View at: Publisher Site | Google Scholar
  12. W. Chuakul, P. Saralamp, W. Paonil, R. Temsiririrkkul, and T. Clayton, Medical Plants in Thailand, vol. II, Amarin, Bangkok, Thailand, 1997.
  13. A. Abdul Rahuman, G. Gopalakrishnan, P. Venkatesan, and K. Geetha, “Isolation and identification of mosquito larvicidal compound from Abutilon indicum (Linn.) Sweet,” Parasitology Research, vol. 102, no. 5, pp. 981–988, 2008. View at: Publisher Site | Google Scholar
  14. S. S. Deokule and M. W. Patale, “Pharmacognostic study of Abutilon indicum, (L.) Sweet,” Journal of Phytological Research, vol. 15, pp. 1–6, 2002. View at: Google Scholar
  15. E. Porchezhian and S. H. Ansari, “Hepatoprotective activity of Abutilon indicum on experimental liver damage in rats,” Phytomedicine, vol. 12, no. 1-2, pp. 62–64, 2005. View at: Publisher Site | Google Scholar
  16. J. Parekh and S. Chanda, “Antibacterial and phytochemical studies on twelve species of Indian medicinal plants,” African Journal of Biomedical Research, vol. 10, pp. 175–181, 2007. View at: Google Scholar
  17. M. Ahmed, S. Amin, M. Islam, M. Takahashi, E. Okuyama, and C. F. Hossain, “Analgesic principle from Abutilon indicum,” Pharmazie, vol. 55, no. 4, pp. 314–316, 2000. View at: Google Scholar
  18. K. R. Kohli, G. Shilin, and S. A. Kolhapure, “Evaluation of the clinical efficacy and safety of Diabecon in NIDDM,” The Antiseptic, vol. 101, pp. 487–494, 2004. View at: Google Scholar
  19. S. K. Mitra, S. Gopumadhavan, T. S. Muralidhar, S. D. Anturlikar, and M. B. Sujatha, “Effect of a herbomineral preparation D-400 in streptozotocin-induced diabetic rats,” Journal of Ethnopharmacology, vol. 54, no. 1, pp. 41–46, 1996. View at: Publisher Site | Google Scholar
  20. A. R. Kishan, M. Ajitha, and K. Rajanarayana, “Antidiabetic, antihyperlipidemic and free radical scavenging activities of an Ayurvedic medicine,” Indian Drugs, vol. 37, no. 3, pp. 130–132, 2000. View at: Google Scholar
  21. M. Bhat, S. K. Kothiwale, A. R. Tirmale, S. Y. Bhargava, and B. N. Joshi, “Antidiabetic properties of Azardiracta indica and Bougainvillea spectabilis: in vivo studies in murine diabetes model,” Evidence-Based Complementary and Alternative Medicine. In press. View at: Publisher Site | Google Scholar
  22. P. Peungvicha, S. S. Thirawarapan, R. Temsiririrkkul, H. Watanabe, J. Kumar Prasain, and S. Kadota, “Hypoglycemic effect of the water extract of Piper sarmentosum in rats,” Journal of Ethnopharmacology, vol. 60, no. 1, pp. 27–32, 1998. View at: Publisher Site | Google Scholar
  23. A. O. Abdel-Zaher, S. Y. Salim, M. H. Assaf, and R. H. Abdel-Hady, “Antidiabetic activity and toxicity of Zizyphus spina-christi leaves,” Journal of Ethnopharmacology, vol. 101, no. 1–3, pp. 129–138, 2005. View at: Publisher Site | Google Scholar
  24. S.-H. Lee, K. Yamaguchi, J.-S. Kim et al., “Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner,” Carcinogenesis, vol. 27, no. 5, pp. 972–981, 2006. View at: Publisher Site | Google Scholar
  25. F. Sanchez de Medina, M. J. Gamez, I. Jimenez, J. Jimenez, J. I. Osuna, and A. Zarzuelo, “Hypoglycemic activity of juniper 'berries',” Planta Medica, vol. 60, no. 3, pp. 197–200, 1994. View at: Publisher Site | Google Scholar
  26. W. Shang, Y. Yang, L. Zhou, B. Jiang, H. Jin, and M. Chen, “Ginsenoside Rb1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes,” Journal of Endocrinology, vol. 198, no. 3, pp. 561–569, 2008. View at: Publisher Site | Google Scholar
  27. J. Lee and M.-S. Kim, “The role of GSK3 in glucose homeostasis and the development of insulin resistance,” Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. S49–S57, 2007. View at: Publisher Site | Google Scholar
  28. H. Yki-Järvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1158, 2004. View at: Publisher Site | Google Scholar
  29. H. Zhang, H. Matsuda, S. Nakamura, and M. Yoshikawa, “Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 11, pp. 3272–3277, 2008. View at: Publisher Site | Google Scholar
  30. C. Kausch, J. Krützfeldt, A. Witke et al., “Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 664–674, 2001. View at: Publisher Site | Google Scholar
  31. F. Chiarelli and D. Di Marzio, “Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives,” Vascular Health and Risk Management, vol. 4, no. 2, pp. 297–304, 2008. View at: Google Scholar
  32. A. J. Krentz and C. J. Bailey, “Oral antidiabetic agents: current role in type 2 diabetes mellitus,” Drugs, vol. 65, no. 3, pp. 385–411, 2005. View at: Publisher Site | Google Scholar
  33. T. Szkudelski, “The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas,” Physiological Research, vol. 50, no. 6, pp. 537–546, 2001. View at: Google Scholar
  34. K. Hatao, K. Kaku, M. Matsuda, M. Tsuchiya, and T. Kaneko, “Sulfonylurea stimulates liver fructose-2,6-bisphosphate formation in proportion to its hypoglycemic action,” Diabetes Research and Clinical Practice, vol. 1, pp. 49–53, 1985. View at: Google Scholar
  35. M. Matsuda, K. Kaku, and T. Kaneko, “Regulation of muscle fructose 2, 6-bisphosphate levels by sulfonylureas,” Endocrinologia Japonica, vol. 33, no. 6, pp. 913–917, 1986. View at: Google Scholar
  36. E. Tsiani, T. Ramlal, L. A. Leiter, A. Klip, and I. G. Fantus, “Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide,” Endocrinology, vol. 136, no. 6, pp. 2505–2512, 1995. View at: Google Scholar
  37. E. D. Rosen and B. M. Spiegelman, “Molecular regulation of adipogenesis,” Annual Review of Cell and Developmental Biology, vol. 16, pp. 145–171, 2000. View at: Publisher Site | Google Scholar
  38. S. R. Farmer, “Transcriptional control of adipocyte formation,” Cell Metabolism, vol. 4, no. 4, pp. 263–273, 2006. View at: Publisher Site | Google Scholar
  39. M. Hassan, C. E. Yazidi, J.-F. Landrier, D. Lairon, A. Margotat, and M.-J. Amiot, “Phloretin enhances adipocyte differentiation and adiponectin expression in 3T3-L1 cells,” Biochemical and Biophysical Research Communications, vol. 361, no. 1, pp. 208–213, 2007. View at: Publisher Site | Google Scholar
  40. T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tobe, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1784–1792, 2006. View at: Publisher Site | Google Scholar
  41. J. J. Díez and P. Iglesias, “The role of the novel adipocyte-derived hormone adiponectin in human disease,” European Journal of Endocrinology, vol. 148, no. 3, pp. 293–300, 2003. View at: Publisher Site | Google Scholar
  42. S. J. Robins, “PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates,” Journal of Cardiovascular Risk, vol. 8, no. 4, pp. 195–201, 2001. View at: Publisher Site | Google Scholar
  43. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at: Publisher Site | Google Scholar
  44. P. R. Shepherd and B. B. Kahn, “Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus,” The New England Journal of Medicine, vol. 341, no. 4, pp. 248–257, 1999. View at: Publisher Site | Google Scholar
  45. G. I. Shulman, “Cellular mechanisms of insulin resistance,” Journal of Clinical Investigation, vol. 106, no. 2, pp. 171–176, 2000. View at: Google Scholar
  46. N. Takahashi, M. Nagamine, S. Tanno, W. Motomura, Y. Kohgo, and T. Okumura, “A diacylglycerol kinase inhibitor, R59022, stimulates glucose transport through a MKK3/6-p38 signaling pathway in skeletal muscle cells,” Biochemical and Biophysical Research Communications, vol. 360, no. 1, pp. 244–250, 2007. View at: Publisher Site | Google Scholar
  47. Y. Yamamoto, Y. Yoshimasa, M. Koh et al., “Constitutively active mitogen-activated protein kinase kinase increases GLUT1 expression and recruits both GLUT1 and GLUT4 at the cell surface in 3T3-L1 adipocytes,” Diabetes, vol. 49, no. 3, pp. 332–339, 2000. View at: Google Scholar
  48. S. H. Kim, E.-J. Shin, E.-D. Kim, T. Bayaraa, S. C. Frost, and C.-K. Hyun, “Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes,” Biological and Pharmaceutical Bulletin, vol. 30, no. 11, pp. 2120–2125, 2007. View at: Publisher Site | Google Scholar
  49. N. Liu, L. Y. Jia, and Q. S. Sun, “Chemical constituents of Abutilon indicum (L.) Sweet,” Journal of Shenyang Pharmaceutical University, vol. 26, pp. 196–197, 2009. View at: Google Scholar
  50. J. Chen, J. Liu, L. Zhang et al., “Pentacyclic triterpenes. Part 3: synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2915–2919, 2006. View at: Publisher Site | Google Scholar

Copyright © 2011 Chutwadee Krisanapun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.